300
Participants
Start Date
May 19, 2020
Primary Completion Date
June 30, 2025
Study Completion Date
December 30, 2025
HAIC
administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
Bevacizumab plus Atezolizumab
Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
Bevacizumab Biosimilar IBI305 plus sintilimab
Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
Lenvatinib
8mg; p.o.; q.d.
Sorafenib
400mg; p.o. bid
Donafenib
200mg; p.o. bid
Regorafenib
160 mg; p.o.; q.d.
apatinib plus camrelizumab
Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
Anti-PD-1 monoclonal antibody
HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
RECRUITING
The Second Affiliated Hospital of Fujian Medical University, Quanzhou
RECRUITING
TongjiHospital, Wuhan
Collaborators (1)
Chinese Cooperative Group of Liver Cancer
OTHER
Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province
OTHER
Haplox Biotechnology Co., Ltd.
INDUSTRY
Geneplus-Beijing Co. Ltd.
INDUSTRY
The Second Affiliated Hospital of Fujian Medical University
OTHER
Ze-yang Ding, MD
OTHER